| __timestamp | Protagonist Therapeutics, Inc. | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1860000 | 7751000 |
| Thursday, January 1, 2015 | 2963000 | 10251000 |
| Friday, January 1, 2016 | 6961000 | 9575000 |
| Sunday, January 1, 2017 | 11779000 | 10912000 |
| Monday, January 1, 2018 | 13697000 | 11049000 |
| Tuesday, January 1, 2019 | 15749000 | 11646000 |
| Wednesday, January 1, 2020 | 18638000 | 13265000 |
| Friday, January 1, 2021 | 27196000 | 25805000 |
| Saturday, January 1, 2022 | 31739000 | 35182000 |
| Sunday, January 1, 2023 | 33491000 | 94999000 |
Cracking the code
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Protagonist Therapeutics, Inc. and Viridian Therapeutics, Inc. have shown distinct strategies over the past decade. From 2014 to 2023, Protagonist's SG&A expenses grew by approximately 1,700%, starting at $1.86 million and peaking at $33.49 million. Meanwhile, Viridian's expenses surged by over 1,100%, from $7.75 million to a staggering $94.99 million in 2023.
Despite Viridian's higher absolute costs, both companies have shown a consistent upward trend, reflecting their growth and expansion efforts. The data suggests that while Protagonist maintains a more conservative approach, Viridian's aggressive spending could indicate a strategy focused on rapid scaling. Investors and stakeholders should consider these trends when evaluating the companies' operational efficiencies and long-term sustainability.
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and Protagonist Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Sanofi or Viridian Therapeutics, Inc.
Selling, General, and Administrative Costs: Vertex Pharmaceuticals Incorporated vs Viridian Therapeutics, Inc.
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Protagonist Therapeutics, Inc.
Comparing SG&A Expenses: Sarepta Therapeutics, Inc. vs Viridian Therapeutics, Inc. Trends and Insights
Comparing SG&A Expenses: Alpine Immune Sciences, Inc. vs Viridian Therapeutics, Inc. Trends and Insights
ADMA Biologics, Inc. vs Protagonist Therapeutics, Inc.: SG&A Expense Trends
Viking Therapeutics, Inc. or Protagonist Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of CRISPR Therapeutics AG and Viridian Therapeutics, Inc.
Breaking Down SG&A Expenses: Veracyte, Inc. vs Viridian Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Amicus Therapeutics, Inc. and Viridian Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of HUTCHMED (China) Limited and Viridian Therapeutics, Inc.